Blepharitis
is an inflammation of the eyelids that occurs over time. Blepharitis affects
the area of the eyelid where the eyelashes grow and happens when tiny oil
glands around this area become clogged, causing discomfort and redness. High
sensitivity to light, loss of eyelashes, watery eyes, burning sensation in the
eyes, greasy eyelids, itchy eyes, red and swollen eyes, flaking of skin around
the eyes, crusted eyelashes after waking up, more frequent blinking, abnormal
eyelash growth, and stinging sensation in the eyes are all symptoms of
blepharitis. Seborrheic dermatitis, or dandruff of the eyebrows and scalp,
bacterial infection, clogged oil glands, dysfunctional oil glands, and rosacea
are all symptoms of blepharitis. Eye drugs, contact lens solutions, eye
make-up, and eyelash lice or mites can also induce allergic responses.
Blepharitis Treatment Market
Drivers:-
Because of
the rising frequency of ocular problems among the senior population, the blepharitis
treatment market is predicted to increase significantly. Blepharitis
mainly affects adults over the age of 50, according to a survey done by the
American Academy of Ophthalmology in 2014. Male ocular patients had 37 percent
blepharitis, while female ophthalmic patients have 47 percent. The market is
also predicted to rise significantly as the number of medications in
development grows. For example, InSite Vision's medication ISV-305 is currently
in phase 3 clinical studies. ISV-305 is used to treat people who are
experiencing early signs of blepharitis.
Blepharitis Treatment Market Regional
Analysis:-
Because of
the growing elderly population, the introduction of new products, and the
growing number of ophthalmology patients in the region, North America is likely
to dominate the blepharitis treatment market. According to a poll done by the
United States Population Reference Bureau, the ageing population in the United
States increased by 24% in 2016, compared to 15% in 2014. Due to an increase in
product launches in the region, Europe is likely to experience substantial
growth. For example, Scope Ophthalmic introduced the Moist Heat Mask in 2017, a
device that aids in the treatment of blepharitis by freeing the oil in the
Meibomian glands and enabling it to flow more freely. It softens eye lash
debris, prevents natural tear film evaporation, replenishes moisture in the eye
and surrounding area, and improves tear film lipid quality. MibO Thermoflo was
launched in 2015 by MiBo Medical Group, a company based in the United States.
Comments
Post a Comment